Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

AHR and tryptophan metabolism: a collaborative dynamics of immune regulation.

Zhu J. and J Van den Eynde B., (2023), Genes and immunity

Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.

Carroll TM. et al, (2023), Cancer cell, 41, 1222 - 1241.e7

Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC.

Leung CSK. and Van den Eynde BJ., (2022), Cancer cell, 40, 903 - 905

Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.

Lahman MC. et al, (2022), Science translational medicine, 14

Functional Differences between Proteasome Subtypes.

Abi Habib J. et al, (2022), Cells, 11

Systemic tryptophan homeostasis.

Klaessens S. et al, (2022), Frontiers in molecular biosciences, 9

Rational Design of Original Fused-Cycle Selective Inhibitors of Tryptophan 2,3-Dioxygenase.

Kozlova A. et al, (2021), Journal of medicinal chemistry, 64, 10967 - 10980

Arid5a: A Missing Link between EMT and Tumoral Immune Resistance

Van den Eynde BJ., (2021), Cancer Immunology Research, 9, 854 - 854

Load More